Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Medtronic
Dow
Baxter
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Trastuzumab emtansine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Trastuzumab emtansine: Sponsors, patents, clinical trial progress

Trastuzumab emtansine is an investigational drug.

There have been 68 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.

There are thirty US patents protecting this investigational drug and six hundred and seventy-five international patents.

Recent Clinical Trials for Trastuzumab emtansine
TitleSponsorPhase
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerAstraZeneca UK LimitedPhase 1
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerMerck Sharp & Dohme Corp.Phase 1
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerDaiichi Sankyo, Inc.Phase 1

See all Trastuzumab emtansine clinical trials

Clinical Trial Summary for Trastuzumab emtansine

Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine

See all Trastuzumab emtansine clinical trials

US Patents for Trastuzumab emtansine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trastuzumab emtansine   Start Trial Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Array BioPharma Inc. (Boulder, CO)   Start Trial
Trastuzumab emtansine   Start Trial Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Trastuzumab emtansine   Start Trial Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   Start Trial
Trastuzumab emtansine   Start Trial Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Start Trial
Trastuzumab emtansine   Start Trial Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   Start Trial
Trastuzumab emtansine   Start Trial Compositions and methods for detecting protease activity in biological systems CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trastuzumab emtansine

Drugname Country Document Number Estimated Expiration Related US Patent
Trastuzumab emtansine Argentina 074052 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2009308465 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2015200511 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2017268517 2028-10-22   Start Trial
Trastuzumab emtansine Brazil PI0919873 2028-10-22   Start Trial
Trastuzumab emtansine Canada 2741313 2028-10-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
Express Scripts
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.